"BRCA1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). It contains an N-terminal RING FINGER DOMAIN and is a PROTEIN PHOSPHATASE 1 regulatory subunit. In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
| Descriptor ID |
D019313
|
| MeSH Number(s) |
D12.776.313.125 D12.776.624.776.100 D12.776.660.100 D12.776.744.100 D12.776.930.137
|
| Concept/Terms |
BRCA1 Protein- BRCA1 Protein
- Breast Cancer Type 1 Susceptibility Protein
- Breast Cancer 1 Protein
- Ring Finger Protein 53
- BRCA1 Gene Product
- Breast Cancer 1 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "BRCA1 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA1 Protein".
This graph shows the total number of publications written about "BRCA1 Protein" by people in this website by year, and whether "BRCA1 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2010 | 4 | 0 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "BRCA1 Protein" by people in Profiles.
-
BRCA1-BARD1 regulates transcription through BRD4 in Xenopus nucleoplasmic extract. Nucleic Acids Res. 2021 04 06; 49(6):3263-3273.
-
Characterization of metabolic responses, genetic variations, and microsatellite instability in ammonia-stressed CHO cells grown in fed-batch cultures. BMC Biotechnol. 2021 01 08; 21(1):4.
-
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 01; 2(1):66-82.
-
PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study. J Cutan Pathol. 2021 Apr; 48(4):597-600.
-
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice. Cancer Res. 2020 10 01; 80(19):4172-4184.
-
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555.
-
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One. 2019; 14(12):e0226714.
-
Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol. 2020 Feb; 27(2):367-372.
-
Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019 May; 119(6):777-783.
-
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Mol Cancer Res. 2018 07; 16(7):1092-1102.